LAS VEGAS, June 10, 2024 /PRNewswire/ -- DelveInsight's Postherpetic Neuralgia Market Insights report includes a comprehensive understanding of current treatment practices, postherpetic neuralgia emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Postherpetic Neuralgia Market Report Discover which therapies are expected to grab the major postherpetic neuralgia market share @ Postherpetic Neuralgia Market Report Postherpetic Neuralgia Overview Postherpetic neuralgia is a frequent complication of shingles, which arises from the reactivation of the varicella-zoster virus (VZV) that remains dormant in the body after an initial varicella infection. The shingles outbreak damages sensory nerves, causing abnormal signals to be sent to the brain and resulting in pain.
This condition often includes symptoms like dysesthesia, paresthesia, allodynia, and hyperalgesia. These symptoms can persist for many years, severely disrupting sleep, mood, and overall quality of life. Apart from old age and immunosuppression, conditions such as systemic lupus erythematosus, diabetes, and recent trauma can increase the risk of developing postherpetic neuralgia.
Factors such as advanced age, severe acute pain during the initial shingles infection, a rash spreading beyond the initial dermatome, and a weak.